EUVIMEDEUVIMED entdecken
Crossref

Sculponeatin A induces mitochondrial dysfunction in non‐small cell lung cancer through WWP2‐mediated degradation of mitochondrial STAT3

Fang Wan, Chen Qian, Xuewen Liu, Yifan Zhong, Wenkang Peng, Liang Zhang, Xiangrong Zhan, Yongtong Huang, Chengyu Zhang, Jiu Wang, Yuan Si, Ying Liu

British Journal of Pharmacology · 2025-06 · 182 (12) · 2662-2681

DOI: 10.1111/bph.17460 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 24.02.2025. Verfasst von Fang Wan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, STAT3 Transcription Factor, Mitochondria. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Foundation of Hubei Provincial Department of Science and Technology, Advantages Discipline Group Project in Higher Education of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose The phosphorylation of signal transducer and activator of transcription 3 (STAT3) monomer at S727 promotes its mitochondrial localisation and regulates mitochondrial function, thus exerting a protective effect on tumour cells. However, no inhibitor drugs targeting mitochondrial STAT3 (mitoSTAT3) or S727‐STAT3 phosphorylation have been identified. Here, we report a novel diterpenoid extracted from Isodon sculponeatus , sculponeatin A (sptA), induces mitochondrial dysfunction in non‐small cell lung cancer (NSCLC) by targeting mitoSTAT3 degradation. Experimental Approach xCELLigence real‐time cell analysis assay and high‐content analysis were performed to measure cytotoxicity. Mitochondrial function was assessed by transmission electron microscopy, mitochondrial permeability transition pore opening and Seahorse cellular flux assays. The effects of sptA on the upstream signalling pathway of mitochondrial dysfunction were measured by Western blot, gene alterations and other approaches. Immunofluorescence and live cell imaging were performed to visualise the expression and position of mitoSTAT3. Nude mice and zebrafish were modelled with subcutaneous xenografts. Pharmacokinetics of sptA were examined in rats. Drug toxicity was evaluated in zebrafish. Key Results sptA inhibited mitochondrial respiration in NSCLC cells. sptA induced mitochondrial dysfunction by promoting the degradation of mitoSTAT3. sptA promoted WW domain containing E3 ubiquitin protein ligase 2 (WWP2)‐mediated ubiquitination and degradation of mitoSTAT3 through direct binding. sptA inhibited tumour growth in vivo. Evaluation of drug toxicity in zebrafish showed that overdose of sptA may cause heart damage. Conclusions and Implications These findings suggest that pharmacological targeting the degradation of mitoSTAT3 by sptA may provide therapeutic benefits against NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsSTAT3 Transcription FactorMitochondriaUbiquitin-Protein LigasesDiterpenesAnimalsHumansMice, NudeZebrafishMiceRatsMaleRats, Sprague-DawleyProteolysisCell Line, Tumor

Stichwörter der Autor:innen

WWP2mitoSTAT3mitochondrial dysfunctionnon‐small cell lung cancersculponeatin A

Substanzen

STAT3 Transcription FactorUbiquitin-Protein LigasesDiterpenesSTAT3 protein, human

Autor:innen und Institutionen

  • Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan, China.
  • Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, China.
  • Guangdong Provincial Key Laboratory for Research and Evaluation of Pharmaceutical Preparations, Center for New Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, China.
  • Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Shiyan, China.

Förderung

  • National Natural Science Foundation of China
  • Foundation of Hubei Provincial Department of Science and Technology
  • Advantages Discipline Group Project in Higher Education of Hubei Province
  • Natural Science Foundation of Hubei Provincial Department of Education
  • National Training Program of Innovation and Entrepreneurship for Undergraduates

Zitieren

APA

Wan, F., Qian, C., Liu, X., Zhong, Y., Peng, W., Zhang, L., Zhan, X., Huang, Y., Zhang, C., Wang, J., Si, Y., & Liu, Y. (2025). Sculponeatin A induces mitochondrial dysfunction in non‐small cell lung cancer through WWP2‐mediated degradation of mitochondrial STAT3. British Journal of Pharmacology, 182(12), 2662-2681. https://doi.org/10.1111/bph.17460

Vancouver

Wan F, Qian C, Liu X, Zhong Y, Peng W, Zhang L, et al. Sculponeatin A induces mitochondrial dysfunction in non‐small cell lung cancer through WWP2‐mediated degradation of mitochondrial STAT3. British Journal of Pharmacology. 2025;182(12):2662-2681. doi:10.1111/bph.17460

BibTeX
@article{Wan2025,
  author = {Wan, Fang and Qian, Chen and Liu, Xuewen and Zhong, Yifan and Peng, Wenkang and Zhang, Liang and Zhan, Xiangrong and Huang, Yongtong and Zhang, Chengyu and Wang, Jiu and Si, Yuan and Liu, Ying},
  title = {Sculponeatin A induces mitochondrial dysfunction in non‐small cell lung cancer through WWP2‐mediated degradation of mitochondrial STAT3},
  journal = {British Journal of Pharmacology},
  year = {2025},
  volume = {182},
  number = {12},
  pages = {2662--2681},
  doi = {10.1111/bph.17460}
}
Kostenlos starten →